Senti Biosciences (NASDAQ:SNTI) Price Target Cut to $11.00 by Analysts at Chardan Capital

Senti Biosciences (NASDAQ:SNTI) had its target price trimmed by Chardan Capital from $13.00 to $11.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research firms have also commented on SNTI. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a report on Thursday, January 22nd. Wall Street Zen upgraded Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.50.

Senti Biosciences Trading Down 2.3%

SNTI opened at $0.77 on Monday. Senti Biosciences has a 12-month low of $0.77 and a 12-month high of $5.10. The firm has a market capitalization of $20.29 million, a PE ratio of -0.24 and a beta of 2.12. The firm has a 50 day moving average of $0.94 and a two-hundred day moving average of $1.38.

Senti Biosciences (NASDAQ:SNTI) last released its quarterly earnings data on Friday, March 27th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.10). The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $1.00 million. As a group, analysts predict that Senti Biosciences will post -14.54 EPS for the current fiscal year.

Institutional Trading of Senti Biosciences

A number of hedge funds have recently added to or reduced their stakes in SNTI. Jane Street Group LLC acquired a new stake in Senti Biosciences during the fourth quarter valued at $40,000. Virtu Financial LLC acquired a new position in shares of Senti Biosciences in the fourth quarter worth about $46,000. Citadel Advisors LLC purchased a new stake in shares of Senti Biosciences during the 3rd quarter worth about $117,000. Geode Capital Management LLC boosted its stake in shares of Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares in the last quarter. Finally, Armistice Capital LLC acquired a new stake in shares of Senti Biosciences during the 2nd quarter valued at about $1,883,000. 25.70% of the stock is owned by hedge funds and other institutional investors.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.